Latest news with #NGS
Medscape
an hour ago
- Health
- Medscape
Fast Five Quiz: Cancer Diagnostics and Precision Medicine
Over the past decade, precision medicine has transformed cancer diagnostics and treatment by tailoring therapy to a patient's tumor biology based on molecular alterations rather than histologic subtypes or origins. Precision oncology often relies on molecular profiling through next-generation sequencing (NGS) to identify genomic events that can guide management. Techniques like targeted panels, whole-exome sequencing (WES), and whole-genome sequencing (WGS) provide different analysis levels, chosen based on tumor type, tissue, and therapy relevance. How much do you know about cancer diagnostics and precision medicine? Test your knowledge with this quick quiz. WGS is an NGS method that analyzes the entire DNA sequence of an organism, including both coding and noncoding regions. WGS offers broad genomic coverage, detecting structural variants, intergenic mutations, and copy number changes often missed by targeted methods. Clinically, it has been useful in identifying ERBB2 ( HER2 ) amplifications in breast cancer or complex epidermal growth factor receptor ( EGFR ) alterations in lung cancer that might not be captured by smaller panels, helping guide targeted therapy. However, its lower sequencing depth (30-60×) typically limits the detection of low-frequency variants in heterogeneous tumors, such as a subclonal TP53 mutation affecting a small subset of cells and potentially impacting treatment response, which WGS may miss due to its lower depth. WES focuses only on the protein-coding regions, offering greater depth than WGS but limited breadth; however, it misses important regulatory and noncoding mutations. For example, TERT promoter mutations in glioblastoma are clinically relevant but lie outside the exome and would be missed by WES. Targeted panels are NGS tests that focus on specific disease-related genes and, until recently, were the predominant method used for comprehensive genomic profiling in clinical settings. They offer high depth for detecting low-frequency, actionable mutations but have limited coverage and might miss rare alterations outside the selected genes. Sanger sequencing is a method that reads DNA by generating fragments of varying lengths using chain-terminating nucleotides. It is accurate for small regions but has low throughput and cannot detect low-frequency mutations, making it unsuitable for large-scale cancer genomics. Unlike WGS, which surveys the entire genome, Sanger covers only targeted regions, so it does not offer broad genomic coverage and is therefore not the correct answer. Learn more about molecular profiling in oncology diagnostics. TS panels analyze specific genes relevant to oncology, and by focusing on a smaller subset of the genome (a few dozen to a few hundred genes), these panels require fewer sequencing data, resulting in faster turnaround times and simplified data interpretation compared with WGS or WES. This targeted approach enhances sensitivity for detecting clinically actionable somatic mutations, especially in small or heterogeneous tumor samples. For example, targeted NGS panels in non-small cell lung cancer (NSCLC) can rapidly detect EGFR mutations, ALK rearrangements, and other actionable alterations, allowing oncologists to initiate targeted therapies based on the mutation profile promptly. TS also demands less data storage and computational processing compared with WGS or WES, resulting in faster turnaround times and lower costs. These attributes make TS especially well-suited for clinical settings where accuracy, speed, and cost-effectiveness are paramount Learn more about clinical practice guidelines in the use of precision medicine in oncology. Tissue is generally preferred for initial genomic profiling because it contains a higher concentration of tumor DNA, allowing for more accurate detection of somatic mutations. This is especially important in early-stage cancers or tumors that do not shed much DNA into the bloodstream to be detectable by liquid biopsy. The tissue also allows for additional analyses like immunohistochemistry for PD-L1 or assessment of tumor histology to guide therapy. Further, immunohistochemistry plays an important role in precision medicine by identifying protein biomarkers to help determine the use of immune checkpoint inhibitors in NSCLC, triple-negative breast cancer, and urothelial carcinoma. Blood-based tests (ie, liquid biopsies) generally yield lower tumor DNA and do not inherently offer deeper sequencing but are generally more cost-effective than tissue biopsies. Regulatory agencies currently accept blood-based tests (eg, FDA-approved liquid biopsies), but they are typically used when tissue is unavailable or there is insufficient tissue. Learn more about tissue-based profiling Liquid biopsy, particularly through the analysis of circulating tumor DNA (ctDNA), has emerged as a valuable tool for monitoring MRD after treatment. By detecting small amounts of tumor-derived genetic material in the blood, liquid biopsy enables early identification of molecular relapse, often before clinical or radiographic evidence of recurrence is apparent. This makes it particularly useful in post-treatment surveillance of cancers such as colorectal, breast, and NSCLC. Diagnosing lymphomas typically requires tissue biopsy to assess architectural patterns and immunophenotyping; it is also commonly regarded as the standard for diagnosis. PD-L1 expression is a protein-based biomarker typically measured by immunohistochemistry on tissue samples, not usually through ctDNA. However, researchers have stated, 'ctDNA response is a potential biomarker for predicting the efficacy and prognosis of first-line PD-1 inhibitor therapy combined with chemotherapy' in patients with advanced gastric cancer. ctDNA also has been shown to predict responses in patients using PD-1/PD-L1 immune checkpoint inhibitors. Tumor staging usually relies on imaging modalities and pathologic evaluation rather than ctDNA analysis alone. Learn more about clinical practice guidelines in the use of precision medicine in oncology. A high TMB is considered useful because it is associated with abnormal proteins that make the tumor more recognizable to the immune system. TMB is measured using NGS by counting the number of somatic, nonsynonymous mutations per megabase of DNA; it is typically assessed using WES or large targeted panels. A TMB of 10 or more mutations per megabase is considered 'high,' based on data from the KEYNOTE-158 trial. This led to the FDA approval of an immune checkpoint inhibitor for TMB-high solid tumors, for example. High TMB is not usually linked to fewer side effects; side effect profiles tend to depend on the therapy, not mutation count. Low TMB has been shown to lead to fewer neoantigens and typically less immune visibility. Typically, TMB directly measures the number of mutations, not PD-L1 protein expression. Learn more about immunotherapy diagnostics.
Korea Herald
6 hours ago
- Business
- Korea Herald
Gene Solutions Strengthens China Footprint with Strategic Partnerships in Precision Oncology
BEIJING, June 20, 2025 /PRNewswire/ -- Gene Solutions announces the signing of two strategic Memoranda of Understanding (MOUs) with ZaoDx and Xiong'an MagicBiotech Co., Ltd. These partnerships mark a focused expansion of Gene Solutions' precision oncology efforts into the Chinese market through collaborative technology introduction, research exploration, and localized deployment of its innovative cancer testing platforms. Together, the partnerships reinforce Gene Solutions' long-term commitment to supporting China's healthcare innovation ecosystem with advanced, clinically validated tools for early cancer detection and monitoring. Enabling Early Detection Through Ecosystem Engagement with ZaoDx Gene Solutions and ZaoDx have formed a strategic business alliance to jointly explore the introduction, promotion, and responsible commercialization of advanced early cancer screening technologies in China. This partnership will focus on: CEO of ZaoDx Dr. Chen Zanquan stated: "Cancer is a challenge faced globally, and early detection is crucial for cure. ZAODX is pleased to collaborate with Gene Solutions to advance the conversion and accessibility of innovative cancer screening and diagnosis technologies. I believe our joint efforts will bring tangible benefits to millions of families." "Our collaboration with ZaoDx reflects a shared commitment to bringing global innovation into meaningful local impact," said Jiang Hao, Business Development Manager at Gene Solutions. "By working alongside respected research-driven partners, we can responsibly introduce early detection technology to more patients and providers across the country." Advancing Research Collaboration in Northern China alongside MagicBiotech Gene Solutions and Xiong'an MagicBiotech have signed an MOU to jointly explore the introduction and academic evaluation of next-generation sequencing (NGS)–based oncology technologies across northern China. The collaboration will center on: "Our partnership with MagicBiotech is a cornerstone for advancing precision oncology in China," said Ida Deleskog Lindstrom, Global Medical Affairs Director at Gene Solutions. "By fostering collaborative research and leveraging local expertise, we aim to validate and scale our technologies to meet the region's clinical and scientific needs." Driving Localized Innovation Through Strategic Collaboration These dual partnerships represent a calibrated approach by Gene Solutions to support the introduction and validation of advanced oncology diagnostics in China. Both collaborations are built on mutual strengths—balancing scientific rigor, ethical commercialization, and long-term research-driven engagement. Project-specific initiatives under each MOU will be rolled out progressively in alignment with local regulations and institutional priorities. About ZaoDx ZAODX Early Screening Network is a globally leading platform dedicated to the early detection of diseases, with a core mission to drive the transformation of global healthcare systems from treatment-centric models to a proactive, health-centered paradigm. Guided by the widely recognized principle that "prevention is the most cost-effective and impactful health strategy," ZAODX advocates the global adoption of early screening, early diagnosis, and early treatment — while also drawing inspiration from Traditional Chinese Medicine's wisdom of "treating disease before it occurs." As a truly international and multidisciplinary team, ZAODX brings together key stakeholders across the global healthcare ecosystem — including scientists, entrepreneurs, investors, policymakers, healthcare providers, and public health experts — united by the mission to make health screening accessible and equitable for all. The network has established strategic partnerships with over 1,000 top-tier medical institutions, academic organizations, professional societies, independent laboratories, and healthcare innovators to foster cross-border academic exchange, scientific collaboration, technology translation, industry synergy, and public health education. Committed to global public health goals, ZAODX actively supports initiatives led by the World Health Organization and national health authorities. Through collaborative efforts, ZAODX is building an innovative and inclusive early screening ecosystem — empowering the global fight for earlier prevention, better outcomes, and healthier populations worldwide. About Xiong'An MagicBiotech Xiong'An MagicBiotech is a biotechnology company in Xiongan New Area focusing on "in vitro diagnostic reagents + testing services + artificial intelligence". MagicBiotech is mainly engaged in independent research and development, production and sales of in vitro diagnostic kits for genetic testing. By using multi-omics medical examination data and bioinformatics AI artificial intelligence technology, it provides in vitro diagnostic reagents and medical testing services to medical institutions and patients; in the scientific research and technology service sector, MagicBiotech has always adhered to the concept of innovation-driven, continued to increase R&D investment, and made every effort to build a complete and advanced technology platform system. The system deeply covers cutting-edge fields such as genomics, proteomics, metabolomics, microbiome, and single-cell multi-omics. About Gene Solutions Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring. With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific.
Time of India
a day ago
- Health
- Time of India
ICMR-NIV Pune inaugurates High Performance Computing facility to boost genomic research and pandemic preparedness
Pune: The Indian Council of Medical Research (ICMR) on Wednesday marked a significant milestone in advancing India's public health research capabilities with the inauguration of its first High Performance Computing (HPC) facility at the ICMR-National Institute of Virology (NIV), Pune. The computing cluster named 'Nakshatra' was officially inaugurated by Dr Rajiv Bahl, Secretary of the Department of Health Research (DHR) and Director General of ICMR, according to an official statement from ICMR. "Developed under the Pradhan Mantri Ayushman Bharat Health Infrastructure Mission (PM ABHIM), the HPC facility forms the cornerstone of a new project titled "High Performance Computing Next Generation Sequencing (NGS) Hub". The initiative aims to revolutionize how genomic and bioinformatics data are processed, addressing limitations faced during the COVID-19 pandemic due to conventional computing infrastructure," the statement added. Addressing a gathering regarding the inauguration of the computing facility, the Director General of ICMR commended the institute for its timely and strategic step towards ' Viksit Bharat 2047 ' vision by strengthening the country's genomic surveillance and data analysis capacity. He highlighted how enhanced computing resources are crucial in preparing for technology-driven pandemic preparedness and future public health emergencies. Meanwhile, Director of ICMR-NIV, Dr Naveen Kumar, emphasised the critical role the HPC cluster will play in supporting rapid, data-driven responses to outbreaks. Dr Sarah Cherian, Group Leader of the Bioinformatics and Data Management Group and Principal Investigator of the project, provided a comprehensive overview of the cluster's capabilities and its role in genomic research . According to the official statement, the newly commissioned HPC cluster features twelve compute nodes offering a total of 700 cores and 1 petabyte of storage. "The infrastructure is tailored to support complex bioinformatics workflows, including next-generation sequencing (NGS), transcriptomics, phylogenetics, metagenomics, and structural bioinformatics. Initially, the facility will serve five ICMR institutes across the country, acting as a central repository for sequencing data and extending support to Viral Research and Diagnostic Laboratories (VRDLs) soon, making the institute as a critical hub for outbreak investigations and pandemic preparedness, with the potential to accelerate AI-driven drug and vaccine discovery," the statement added. Highlighting the advantages of the HPC facility, ICMR highlighted how it is a "national investment in speed, precision, and preparedness." The statement mentioned, "By enabling faster analysis of complex genomic data, the facility positions India to detect new disease threats sooner, respond to outbreaks more efficiently, and accelerate AI-driven vaccine and drug development."
Yahoo
2 days ago
- Business
- Yahoo
Clinical Reference Laboratory Services Market to Exceed USD 92 Billion by 2034
Clinical Reference Laboratory Services Market: In-Depth Analysis and Forecast 2025–2034 Luton, Bedfordshire, United Kingdom, June 18, 2025 (GLOBE NEWSWIRE) -- Market Overview The global clinical reference laboratory services market is poised for significant growth, expected to rise from USD 50.12 billion in 2024 to USD 92.07 billion by 2034. This growth represents a Compound Annual Growth Rate (CAGR) of 5.42% over the forecast period. Clinical reference laboratories serve a pivotal role in the modern healthcare ecosystem by providing specialized diagnostic and testing services to healthcare providers. These laboratories are equipped with advanced instruments and staffed with trained professionals, including pathologists, lab technologists, and technicians, all of whom contribute to disease diagnosis, monitoring, and prevention. Download PDF Brochure: These facilities perform a broad array of diagnostic procedures such as blood work, urinalysis, genetic and molecular testing, microbiology analysis, and specialized cytology diagnostics. The results provided by these laboratories empower hospitals, clinics, and physicians to make informed treatment decisions. Moreover, many clinical reference laboratories are deeply involved in research and development, continuously innovating to improve diagnostic methodologies and overall patient outcomes. Technology Insights Traditional laboratory techniques remain dominant in the clinical reference laboratory services market, primarily due to their established use and reliability in routine diagnostics. These include microscopy, culture-based testing, and biochemical analyses, which have long served as the foundation of clinical diagnostics. Routine examinations such as complete blood counts, liver function tests, urinalysis, and metabolic panels continue to rely on these traditional techniques because of their cost-effectiveness, standardization, and accuracy. Nevertheless, the market is also witnessing substantial integration of modern technologies such as automated testing platforms and molecular diagnostics. Automation enhances operational efficiency by leveraging robotics and high-throughput instrumentation, reducing human error, and speeding up processes. Molecular diagnostics, especially techniques like polymerase chain reaction (PCR) and next-generation sequencing (NGS), provide high sensitivity and specificity for detecting genetic mutations and disease markers. This technology is essential in personalized medicine, infectious disease diagnosis, and oncology. Segment Analysis by Type Within the clinical reference laboratory services market, the clinical chemistry segment holds the largest share. Clinical chemistry involves the biochemical assessment of blood and other bodily fluids to monitor glucose levels, lipid profiles, liver and kidney functions, and electrolyte balance. These tests are not only routine but also essential for diagnosing and managing conditions such as diabetes, cardiovascular disorders, and hepatic diseases. Genetics testing represents a fast-growing segment, as it allows for the identification of inherited disorders, drug responsiveness, and cancer predisposition. Applications include pharmacogenomics, cancer risk analysis, carrier screening, and prenatal testing. The continuous advancement in genomics and declining costs of genetic sequencing are expected to fuel the growth of this segment. The microbiology and cytology segment also plays a crucial role, especially in diagnosing infectious diseases and cancer. Microbiology tests focus on identifying pathogens including bacteria, viruses, fungi, and parasites, while cytology involves microscopic analysis of cells, often used in Pap smears and cancer diagnostics. Market Drivers One of the primary drivers of market growth is the increasing global prevalence of chronic diseases. Conditions such as diabetes, cardiovascular disorders, cancer, and autoimmune diseases are on the rise due to aging populations, urban lifestyles, and sedentary habits. Clinical reference laboratories are instrumental in early detection, monitoring, and management of these chronic conditions through a range of diagnostic tools including molecular diagnostics and clinical chemistry. The need for continual monitoring and regular check-ups for chronic disease patients ensures a sustained demand for laboratory testing services. As awareness grows about the benefits of early diagnosis, especially for conditions like cancer and diabetes, the role of clinical reference laboratories becomes increasingly vital in providing specialized and accurate test results. Market Restraints Despite the positive growth outlook, data privacy concerns present a major challenge for the clinical reference laboratory services market. These laboratories handle vast amounts of sensitive health data, including genetic and biometric information, which are subject to stringent privacy regulations such as HIPAA (U.S.) and GDPR (EU). The risk of data breaches and cyberattacks in the healthcare sector has heightened concerns among patients and healthcare providers. Compliance with regulatory frameworks requires significant investment in cybersecurity infrastructure, data encryption, and staff training, which may increase operational costs and complicate service delivery. These challenges can hinder market adoption and slow down the pace of innovation. Opportunities for Growth The continuous development of novel diagnostic tests offers tremendous growth opportunities for the clinical reference laboratory services market. Advancements in genomics, proteomics, and molecular biology have enabled the creation of highly specific diagnostic tools. New tests that enable earlier disease detection and allow for precision medicine are increasingly being incorporated into laboratory services. The growing demand for personalized healthcare solutions is further fueling innovation. Clinical reference laboratories are strategically positioned to lead this transformation, thanks to their capabilities in complex testing and large-scale data analytics. With healthcare moving toward value-based and preventive care, the introduction of new diagnostic modalities will significantly enhance the role of laboratories in guiding clinical decisions. Emerging Trends Several trends are shaping the future of the clinical reference laboratory services market: Molecular Diagnostics Expansion: Technologies like NGS and PCR are being widely adopted for their precision and speed in detecting diseases at the molecular level. Liquid Biopsy Adoption: Non-invasive blood tests for cancer diagnosis and monitoring are gaining popularity, offering alternatives to traditional tissue biopsies. Point-of-Care Testing: The rise of rapid testing kits and devices is facilitating decentralized diagnostics, allowing labs to extend services to rural and underserved regions. Artificial Intelligence (AI) Integration: AI and machine learning algorithms are increasingly used to interpret complex datasets and support decision-making in diagnostics. Telepathology and Remote Consultation: Digital platforms now enable pathologists to analyze slides remotely, improving access to expert opinions and reducing turnaround time. Focus on Cybersecurity: With digitalization, securing sensitive patient information against data breaches has become a top priority. Buy Now: Competitive Landscape The clinical reference laboratory services market features intense competition, with leading players investing in innovation, partnerships, and acquisitions to strengthen their market positions. Major companies include: Laboratory Corporation of America (LabCorp) Quest Diagnostics Sonic Healthcare SYNLAB International OPKO Health LifeLabs Medical Laboratory Services DIAN Diagnostics Eurofins Scientific Exact Sciences Enzo Biochem Lal PathLabs Adicon Clinical Laboratories BML Laboratories Spectra Laboratories Recent developments reflect strong market activity. For instance, Quest Diagnostics launched MelaNodal Predict for personalized melanoma treatment. SYNLAB unveiled a novel test for bipolar disorder, while Sonic Healthcare partnered with Proteomics International to distribute the PromarkerD test for diabetic kidney disease in the U.S. Unilabs expanded its footprint in the Netherlands by acquiring Saltro, enhancing its diagnostic capabilities across Europe. Regional Outlook The Americas are expected to lead the global market, driven by a robust network of clinical laboratories and the presence of major industry players. The United States, in particular, contributes significantly to the regional market due to high healthcare spending, innovation, and government support for diagnostic research. Europe is anticipated to be the second-largest market during the forecast period. Countries such as Germany and France are witnessing a trend toward laboratory outsourcing and technological upgrades. An aging population and increasing incidence of chronic diseases further propel the demand for diagnostic services in the region. Asia Pacific is emerging as a high-growth region, supported by healthcare infrastructure development, growing awareness, and increasing government investments in diagnostics. Nations like China and India are expected to witness robust expansion due to rising healthcare demand and favorable regulatory reforms. Segmentation Summary By Type: Clinical Chemistry, Genetics Testing, Microbiology & Cytology, Others By Technology: Traditional Laboratory Techniques, Automated Testing Platforms, Molecular Diagnostics, Digital Technologies By Application: Clinics, Hospitals, Independent Laboratories By Region: North America, Europe, Asia Pacific, South America, Middle East and Africa Recent Developments: 1. Viome Life Sciences (USA) Viome has recently made significant strides in consumer diagnostics by surpassing 500,000 units sold of its AI-powered at-home health testing kits. These kits analyze biological samples—saliva, stool, and blood—using advanced metatranscriptomic sequencing to provide personalized health insights, including diet, supplements, and even early disease risks. What sets Viome apart is its application of machine learning algorithms to interpret RNA expression in the microbiome and human cells. The company has moved beyond wellness applications and entered the clinical diagnostics space, especially with the launch of its oral and throat cancer early detection test. Viome's approach represents a shift toward precision, preventive healthcare using non-invasive, mail-in testing. With backing from major investors like Salesforce's Marc Benioff and Khosla Ventures, Viome is positioning itself as a leader in the transition from generalized healthcare to personalized, data-driven interventions. 2. Lubdub Technologies (Australia) Lubdub Technologies, a medical diagnostics startup based in Queensland, recently received a $100,000 grant from the Australian Heart Foundation through its Catalyst Partnership program. This funding supports the development of three transformative products designed to improve cardiac health monitoring outside of clinical settings. First, a wearable ECG patch capable of replicating hospital-grade diagnostics. Second, a saliva biosensor able to detect five major cardiac biomarkers, including troponin, enabling earlier detection of cardiac events. Third, a novel wearable ultrasound device intended for real-time, non-invasive heart imaging at home. These innovations aim to address the high rates of delayed cardiac diagnosis, especially in rural or underserved populations. Lubdub's technologies are being trialed in Springfield, Queensland, and are expected to reduce preventable hospital admissions and improve survival rates for cardiovascular conditions. 3. Thermo Fisher Scientific (USA) Thermo Fisher Scientific is undergoing a strategic realignment of its diagnostics business, recently announcing plans to sell portions of this division, including its microbiology unit. The segments up for divestiture generate approximately $1.4 billion in annual revenue with operating earnings of around $300 million. The potential sale is expected to raise $4 billion, which Thermo Fisher may reinvest into higher-growth sectors. This marks Thermo Fisher's first major divestment since its anatomical pathology division was sold in 2019. The move comes as the company navigates changing funding environments, particularly in the U.S. where uncertainty around NIH budgets is prompting a shift in priorities. Despite this, Thermo Fisher has pledged a $2 billion investment in U.S. manufacturing facilities to reinforce its long-term commitment to the domestic healthcare ecosystem. The divestment aligns with a broader industry trend of focusing on core, high-margin capabilities in genomics and specialty diagnostics. 4. QuidelOrtho Corporation (USA/UK) QuidelOrtho, a key player in rapid diagnostic testing, has announced the acquisition of LEX Diagnostics, a UK-based company developing ultra-fast molecular diagnostic platforms. LEX's technology is based on rapid thermal cycling, enabling point-of-care (POC) diagnostic results in just 6 to 10 minutes. This acquisition reflects QuidelOrtho's strategic decision to discontinue its existing Savanna® platform and instead integrate LEX's more promising technology into its product pipeline. The move is expected to enhance QuidelOrtho's competitiveness in the growing market for multiplex POC molecular testing, especially for respiratory infections such as influenza and COVID-19. The transaction is currently pending FDA 510(k) approval, which is expected to be obtained in late 2025 or early 2026. By focusing its resources on LEX's platform, QuidelOrtho aims to deliver faster, more accurate diagnostics that can be deployed directly in clinical or even remote settings, improving patient outcomes and healthcare delivery speed. 5. TriCore Reference Laboratories (USA) TriCore Reference Laboratories, a prominent clinical reference lab based in New Mexico, has made significant operational enhancements through logistics and technology partnerships. In early 2025, the company renewed a long-term agreement with MedSpeed, extending their specimen transportation and logistics contract through 2032. This partnership ensures same-day delivery and improved reliability of specimen transport across TriCore's statewide network. Additionally, TriCore has invested in microbiology automation by implementing COPAN's WASPLab™, an advanced platform that automates plating, incubation, and digital imaging of microbiology cultures. This innovation is designed to improve throughput, accuracy, and diagnostic turnaround times. With approximately 1,500 employees and annual revenue nearing $750 million, TriCore continues to expand its influence through both technical modernization and strategic collaborations, strengthening its role in delivering high-quality laboratory services throughout the Southwestern U.S. This report is also available in the following languages: Japanese (臨床検査サービス市場), Korean (임상 참조 실험실 서비스 시장), Chinese (临床参考实验室服务市场), French (Marché des services de laboratoire de référence clinique), German (Markt für klinische Referenzlabordienstleistungen), and Italian (Mercato dei servizi di laboratorio di riferimento clinico), etc. Request Sample Pages: More Research Finding – Limulus Amebocyte Lysate Testing Market The global Limulus Amebocyte Lysate (LAL) testing market is estimated to reach a value of approximately $800 million in 2024, driven by rising regulatory requirements for endotoxin testing across pharmaceuticals and medical devices. The market is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.5% from 2025 to 2034, potentially achieving a market value of around $1.5 billion by 2034. Glow Cell Assay Reagents Market The global Glow Cell Assay Reagents market is valued at approximately $980 million in 2024, with a projected market value reaching around $1.95 billion by 2034. This growth trajectory reflects a robust Compound Annual Growth Rate (CAGR) of 7.2% during the forecast period from 2025 to 2034. Rapid Drug Screen Market The rapid drug screen market is poised for notable growth, with an estimated market value of approximately $2.4 billion in 2024. This sector is projected to reach around $5.1 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 8.1% during the forecast period from 2025 to 2034. PAGOD Syndrome Market The PAGOD Syndrome market is valued at approximately $3.5 billion in 2024, with expectations to reach around $5.2 billion by 2034, driven by increased awareness and advancements in diagnostic methodologies. This translates to a robust Compound Annual Growth Rate (CAGR) of 4.9% during the forecast period of 2025–2034. Endotoxin Detecting Reagents Market The market for endotoxin-detecting reagents is valued at approximately $1.2 billion in 2024, with projections indicating a robust growth trajectory leading to an estimated market value of $1.9 billion by 2034. This growth corresponds to a Compound Annual Growth Rate (CAGR) of about 6.2% over the forecast period from 2025 to 2034. Whole Genome Bisulfite Sequencing Market The Whole Genome Bisulfite Sequencing (WGBS) market is projected to reach a value of approximately $450 million in 2024, driven by increasing applications in epigenetics, cancer research, and genetic disorders. The market is expected to grow significantly over the forecast period from 2025 to 2034, reaching an estimated value of $800 million by 2034. This represents a Compound Annual Growth Rate (CAGR) of about 6.2%. Full Automatic Nucleic Acid Detection Analyzer Market The global market for Full Automatic Nucleic Acid Detection Analyzers is poised to reach an estimated value of $2.5 billion in 2024, driven by increasing demand for precise diagnostic tools in healthcare. The market is projected to expand significantly over the forecast period from 2025 to 2034, with a predicted market value of approximately $4.8 billion. This growth represents a Compound Annual Growth Rate (CAGR) of around 8.4%. Rubella Virus IgM Antibody Assay Kit Market The global Rubella Virus IgM Antibody Assay Kit market is valued at approximately USD 450 million in 2024 and is projected to reach around USD 800 million by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 6.1% during the forecast period from 2025 to 2034. Positive Displacement Pipette Tip Market The global market for positive displacement pipette tips is projected to reach approximately $450 million in 2024, driven by increasing demand in pharmaceutical and biomedical research sectors. The anticipated growth trajectory indicates a market value of around $750 million by 2034, representing a robust expansion fueled by technological advancements and heightened laboratory automation. Wide Orifice Pipette Tip Market The wide orifice pipette tip market is valued at approximately $450 million, driven by increasing demand in laboratories and research environments. Over the forecast period from 2025 to 2034, the market is expected to expand significantly, reaching an estimated value of $700 million by 2034. This growth represents a Compound Annual Growth Rate (CAGR) of about 5.2%. COMP ELISA Market The global COMP ELISA kit market is valued at approximately $150 million in 2024, driven by increased research and diagnostic applications in clinical settings. The market is projected to grow to around $300 million by 2034, with a robust Compound Annual Growth Rate (CAGR) of 7.5% during the forecast period from 2025 to 2034. Anti-Olig2 Antibody Market The global market for Anti-Olig2 antibodies is estimated to reach approximately $150 million in 2024, driven by increasing research activities in neurodegenerative diseases and developments in cancer immunotherapy. During the forecast period from 2025 to 2034, the market is projected to grow at a compound annual growth rate (CAGR) of 6.5%, potentially reaching around $325 million by 2034. RdRp Inhibitor and 3CL Protease Inhibitor Market The global market for RdRp and 3CL protease inhibitors is projected to reach approximately $9.2 billion in 2024, driven by increasing demand for antiviral treatments amid rising viral infections, including those caused by coronaviruses. Over the forecast period from 2025 to 2034, the market is expected to grow significantly, with a projected value of $24 billion by 2034, reflecting a compound annual growth rate (CAGR) of about 10.4%. Aurora Kinase B ELISA Kit Market The global Aurora Kinase B ELISA Kit market is valued at approximately $150 million. This sector is poised for substantial growth, with projections indicating a market value of around $250 million by 2034. This trajectory suggests a Compound Annual Growth Rate (CAGR) of approximately 6% during the forecast period from 2025 to 2034. Aurora Kinase B Antibody Market The global market for Aurora Kinase B antibodies is anticipated to reach approximately USD 1.2 billion in 2024, driven by the increasing prevalence of cancer and advancements in personalized medicine. The market is projected to expand significantly, with a forecasted value of around USD 2.4 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of approximately 7.2% during the period from 2025 to 2034. Real-time Fluorescent Quantitative PCR Kit Market The real-time fluorescent quantitative PCR (qPCR) kit market is valued at approximately $1.5 billion in 2024, driven by increasing demand for accurate and rapid diagnostic tools in research and clinical settings. The market is projected to reach around $2.8 billion by 2034, with a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period of 2025 to 2034. CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@
India Gazette
2 days ago
- Health
- India Gazette
ICMR-NIV Pune inaugurates High Performance Computing facility to boost genomic research and pandemic preparedness
Pune (Maharashtra) [India], June 18 (ANI): The Indian Council of Medical Research (ICMR) on Wednesday marked a significant milestone in advancing India's public health research capabilities with the inauguration of its first High Performance Computing (HPC) facility at the ICMR-National Institute of Virology (NIV), Pune. The computing cluster named 'Nakshatra' was officially inaugurated by Dr Rajiv Bahl, Secretary of the Department of Health Research (DHR) and Director General of ICMR, according to an official statement from ICMR. 'Developed under the Pradhan Mantri Ayushman Bharat Health Infrastructure Mission (PM ABHIM), the HPC facility forms the cornerstone of a new project titled 'High Performance Computing Next Generation Sequencing (NGS) Hub'. The initiative aims to revolutionize how genomic and bioinformatics data are processed, addressing limitations faced during the COVID-19 pandemic due to conventional computing infrastructure,' the statement added. Addressing a gathering regarding the inauguration of the computing facility, the Director General of ICMR commended the institute for its timely and strategic step towards 'Viksit Bharat 2047' vision by strengthening the country's genomic surveillance and data analysis capacity. He highlighted how enhanced computing resources are crucial in preparing for technology-driven pandemic preparedness and future public health emergencies. Meanwhile, Director of ICMR-NIV, Dr Naveen Kumar, emphasised the critical role the HPC cluster will play in supporting rapid, data-driven responses to outbreaks. Dr Sarah Cherian, Group Leader of the Bioinformatics and Data Management Group and Principal Investigator of the project, provided a comprehensive overview of the cluster's capabilities and its role in genomic research. According to the official statement, the newly commissioned HPC cluster features twelve compute nodes offering a total of 700 cores and 1 petabyte of storage. 'The infrastructure is tailored to support complex bioinformatics workflows, including next-generation sequencing (NGS), transcriptomics, phylogenetics, metagenomics, and structural bioinformatics. Initially, the facility will serve five ICMR institutes across the country, acting as a central repository for sequencing data and extending support to Viral Research and Diagnostic Laboratories (VRDLs) soon, making the institute as a critical hub for outbreak investigations and pandemic preparedness, with the potential to accelerate AI-driven drug and vaccine discovery,' the statement added. Highlighting the advantages of the HPC facility, ICMR highlighted how it is a 'national investment in speed, precision, and preparedness.' The statement mentioned, 'By enabling faster analysis of complex genomic data, the facility positions India to detect new disease threats sooner, respond to outbreaks more efficiently, and accelerate AI-driven vaccine and drug development.' (ANI)
